BWX Technologies, Inc.
NYSE•BWXT
CEO: Mr. Rex D. Geveden
Sector: Industrials
Industry: Aerospace & Defense
Listing Date: 2010-08-02
BWX Technologies, Inc., together with its subsidiaries, manufactures and sells nuclear components in the United States, Canada, and internationally. It operates through two segments, Government Operations and Commercial Operations. The Government Operations segment designs and manufactures naval nuclear components, reactors, and nuclear fuel; fabrication activities; and supplies proprietary and sole-source valves, manifolds, and fittings to naval and commercial shipping customers. This segment also involved in manufacture of close-tolerance and equipment for nuclear applications; down blend government stockpiles of uranium; receives, stores, characterizes, dissolves, recovers, and purifies uranium-bearing materials; and supplies research reactor fuel elements for colleges, universities, and national laboratories, as well as components for defense applications. The Commercial Operations segment designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, and reactor components; and other auxiliary equipment, including containers for the storage of nuclear fuel and other high-level nuclear waste. This segment also offers nuclear fuel, fuel handling systems, tooling delivery systems, nuclear grade materials, and precisely machined components, and related services for CANDU nuclear power plants; provides in-plant inspection, maintenance, and modification services, as well as non-destructive examination and tooling/repair solutions; and manufactures medical radioisotopes, radiopharmaceuticals, and medical devices. The company was formerly known as The Babcock & Wilcox Company and changed its name to BWX Technologies, Inc. in June 2015. BWX Technologies, Inc. was founded in 1867 and is headquartered in Lynchburg, Virginia.
Contact Information
Market Cap
$17.92B
P/E (TTM)
54.5
47.3
Dividend Yield
0.5%
52W High
$220.57
52W Low
$84.21
52W Range
Rank15Top 3.1%
6.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$885.82M+0.00%
4-Quarter Trend
EPS
$1.02+0.00%
4-Quarter Trend
FCF
$56.80M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Strong Revenue Growth 2025 Consolidated revenues grew 18.3% to $3.20 B in 2025, driven by Government and Commercial segments increases.
Backlog Increased Significantly Ending backlog totaled $7.26 B, reflecting a substantial $2.42 B increase over December 31, 2024 figures.
Acquisition Boosts Commercial Revenue Commercial revenue surged $329.1 M, largely due to the May 2025 acquisition of Kinectrics, expanding market reach.
Basic EPS Improved Basic earnings per share reached $3.59 USD, showing strong improvement from $3.08 USD reported in 2024.
Risk Factors
Government Funding Dependency Risk Substantial revenue reliance on U.S. Government funding (68% of 2025 revenue) faces Congressional appropriation uncertainty.
Fixed-Price Contract Cost Risk Profitability vulnerable on fixed-price contracts; cost overruns from labor/material fluctuations may cause material losses.
Elevated Cybersecurity Threat Exposure Increased sophisticated cyber threats, including CMMC compliance risks, could severely limit future government contract procurement.
Union Negotiations and Labor Costs Unionized workforce (3,200 members) presents risk of work stoppages or increased labor costs from new agreements.
Outlook
Backlog Revenue Recognition Timeline Expect recognition of approximately 40% of current $7.26 B backlog revenue by the end of 2026.
Growth Through Investment Strategy Pursuing growth via strategic investments and acquisitions, funded by cash from operations or raising debt/equity capital.
Medical Isotope Product Launch Commercial segment plans launch of Molybdenum-99 product line, leveraging medical isotope business platform for growth.
Capital Spending Expected Decline Total capital expenditures were $184.6 M in 2025; heightened spending levels expected to decline as projects complete.
Peer Comparison
Revenue (TTM)
$28.06B
$16.23B
$15.96B
Gross Margin (Latest Quarter)
43.5%
40.4%
37.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ESLT | $40.94B | 88.3 | 12.6% | 8.7% |
| FTAI | $26.66B | 53.2 | 257.0% | 78.9% |
| CW | $25.54B | 52.8 | 18.7% | 25.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
9.1%
Steady Growth
4Q Net Income CAGR
7.2%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 4, 2026
EPS:$0.89
|Revenue:$829.69M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data